Keyphrases
Heavily Pretreated Patients
100%
Tolerability
100%
Safety Self-efficacy
100%
Advanced Clear Cell Renal Cell Carcinoma
100%
Tivozanib
100%
Everolimus
75%
Clear Cell Renal Cell Carcinoma (ccRCC)
75%
Cabozantinib
75%
Lenvatinib
75%
Immune Checkpoint Therapy
75%
Stable Disease
50%
Overall Response Rate
50%
Clinical Benefit Rate
50%
MD Anderson Cancer Center
25%
Radiologists
25%
Overall Survival
25%
Median Overall Survival
25%
Mucositis
25%
Clinical Benefit
25%
Congestive Heart Failure
25%
Tumor Response
25%
Response Evaluation Criteria in Solid Tumors (RECIST)
25%
Partial Response
25%
Progression-free Survival
25%
Median Progression-free Survival
25%
Treatment-related Adverse Events
25%
Performance Status 2
25%
Radiological Response
25%
Hypertension
25%
Treatment Paradigms
25%
Poor Risk
25%
Risk Disease
25%
Metastatic RCC
25%
Advanced Renal Cell Carcinoma
25%
Overall Safety
25%
Sequential Treatment
25%
GI Perforation
25%
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Tivozanib
100%
Diseases
75%
Immunity
75%
Clear Cell
75%
Everolimus
75%
Cabozantinib
75%
Lenvatinib
75%
Overall Survival
50%
Progression Free Survival
50%
Malignant Neoplasm
25%
Neoplasm
25%
Retrospective Study
25%
Adverse Event
25%
Congestive Heart Failure
25%
Mucositis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Tolerability
100%
Tivozanib
100%
Diseases
75%
Everolimus
75%
Cabozantinib
75%
Lenvatinib
75%
Overall Survival
50%
Progression Free Survival
50%
Neoplasm
25%
Retrospective Study
25%
Malignant Neoplasm
25%
Mucosa Inflammation
25%
Congestive Heart Failure
25%
Adverse Event
25%